Olanzapine

Olanzapine is an atypical antipsychotic. It is approved by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia and bipolar disorder. Olanzapine is structurally similar to clozapine and quetiapine. It is a dopamine antagonist and is classified as a thienobenzodiazepine.

Synonyms:

OLANZAPINE FORM I;;

2-Methyl-4-(4-methyl-1-piperazinyl)- 10H-thieno[2,3-b][1,5]benzodiazepine;

2-Methyl-4-(4-methylpiperazin-1-yl)-10H-benzo[b]thieno[2,3-e][1,4]diazepine;

2-Methyl-4-(4-methyl-1-piperazinyl)- 10H-thieno[2,3-b][1,5]benzodiazepine LY-170053;

Integrol;

Properties:

Appearance & Physical State: yellowish crystalline powder

Density: 1.32 g/cm3

Boiling Point: 462.6ºC at 760 mmHg

Melting Point: 195ºC

Flash Point: 233.6ºC:

Vapor Pressure: 0mmHg at 25°C

5-HT Receptor Inhibitors Related Products:

Iloperidone; Clozapine; Agomelatine; Duloxetine hydrochloride; Duloxetine; Alosetron hydrochloride; Palonosetron hydrochloride; Lurasidone; Lurasidone hydrochloride; Ramosetron Hydrochloride; Atomoxetine hcl

[1]. Cipriani A, Rendell JM, Geddes J. Olanzapine in long-term treatment for bipolar disorder. Cochrane Database Syst Rev. 2009 Jan 21;(1):CD004367. doi: 10.1002/14651858.

[2]. Meera Narasimhan, Travis O Bruce, and Prakash Masand. Review of olanzapine in the management of bipolar disorders. Neuropsychiatr Dis Treat. 2007 October; 3(5): 579-587.

[3]. Vieta E. Olanzapine in bipolar disorder. Expert Opin Pharmacother. 2004 Jul;5(7):1613-9.